MedAlliance to be Acquired by Cordis
GENEVA, Oct. 19, 2022 /PRNewswire/ -- Swiss-based medical technology company MedAlliance has announced it has entered into an agreement with Cordis for an acquisition which includes an initial investment of $35M and upfront closing payment of $200M, regulatory achievement milestones of up to $125M and commercial milestones of up to $775M through 2029...
The Grand Hamdan Award goes to two scientists in Australia
DUBAI, UAE, Oct. 19, 2022 /PRNewswire/ -- According to an official announcement made recently in Dubai, Prof. Ian Hector Frazer and the Late Dr. Jian Zhou are the winners of the Grand Hamdan Award for the topic of – Infectious Diseases in the Award's 12th term (2021-2022). Prof. Ian Hector Frazer and Late Dr. Jian Zhou the winners...
STANDIGM TO ATTEND BIO-EUROPE® 2022
Standigm will present AI-driven drug discovery technology at the conference CAMBRIDGE, England, Oct. 19, 2022 /PRNewswire/ -- Standigm, the workflow AI-driven drug discovery company, today announced that it will be represented at the 28th annual BIO-Europe taking place October 24–26, 2022 in Leipzig, Germany. After being delivered digitally over the last two years,...
Rhovac board member resigns due to health reasons
LUND, Sweden, Oct. 18, 2022 /PRNewswire/ -- RhoVac AB (publ) announces today, October 18th 2022, that board member and co-founder Anders Ljungqvist is resigning from the board at his own request due to health reasons. Gunnar Gårdemyr, chairman of the board, comments: "On behalf of the board, I would like to give a warm thank you to Anders for his decisive...
CARsgen Announces NDA Acceptance of BCMA CAR T Zevor-cel (CT053) by China NMPA
SHANGHAI, Oct. 18, 2022 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that the National Medical Products Administration (NMPA) of China has accepted the New Drug Application (NDA) for zevorcabtagene autoleucel ("zevor-cel," R&D...
Zhiyi Biotech Received Clinical Approval from U.S. FDA for SK10 in Chemotherapy-induced Diarrhea
GUANGZHOU, China, Oct. 18, 2022 /PRNewswire/ -- Zhiyi Biotech announced that FDA has approved the Company's Investigational New Drug (IND) application to develop SK10 (Inactivated Bacteroides fragilis) for the treatment of Chemotherapy-induced Diarrhea (CID) . The approval of this IND authorizes Zhiyi Biotech to conduct its Phase 1 clinical trial in the U.S. It's noteworthy that it...
CSafe Continues Expansion of Its Temperature-Controlled Shipping Solutions Portfolio with Introduction of Advanced Reusable Pallet Shipper
Loaded with innovation and technology, CSafeAPS provides superior temperature control and the industry's only in-transit thermal capacity indicator MONROE, Ohio, Oct. 18, 2022 /PRNewswire/ -- CSafe, the largest provider of a complete range of active and passive temperature-controlled shipping solutions for the pharmaceutical industry, announced today the launch of its new advanced...
WeTrade Group Announces the Launch of Global Payment System WTPay and Development Plan of Health Business
BEIJING, Oct. 18, 2022 /PRNewswire/ -- WeTrade Group Inc. ("WeTrade" or the "Company") (NASDAQ: WETG), a global diversified "software as a service" ("SaaS") technology service provider which is committed to providing technical support and digital transformation tools for enterprises across different industries, today announced that it held a press conference (the "Conference") for the launch of its global payment...
ImmVira announced to launch the construction of Global R&D and Commercialization Base
SHENZHEN, China, Oct. 18, 2022 /PRNewswire/ -- On October 18, 2022, ImmVira launched the construction of its Global R&D and Commercialization Base in Suzhou Wuzhong Biomedical Industrial Park (Lifebay), China. The day before, ImmVira's "Shanghai Business and Clinical Center" officially opened on the Shanghai North Bund as well. Global R&D and Commercialization...
EditForce Realizes RNA-editing Technology of “U-to-C”
FUKUOKA, Japan, Oct. 18, 2022 /PRNewswire/ -- EditForce, Inc. (hereinafter "EditForce"), headquartered in Fukuoka, Japan, has realized the world's first RNA-editing technology that enables RNA-editing bases to be changed from "U" to "C," and demonstrated that this technology works even in human cells in a joint study with Professor Takahiro Nakamura, Faculty of Agriculture, Kyushu University. The study opens up...
